Skip to main content
. 2023 Jun 9;13:1153131. doi: 10.3389/fonc.2023.1153131

Table 3.

Clinical outcome of transformed SCLC from LUAD with EP plus anlotinib.

Clinical efficacy Number (%)
CR 1 (10%)
PR 7 (70%)
SD 2 (20%)
PD 0 (0%)
ORR (CR+PR) 8 (80%)
DCR (CR+PR+SD) 10 (100%)

CR, complete remission; PR, partial remission; SD, stable disease; PD, progressive disease; ORR, overall response rate; and DCR, disease control rate.